日本帕金森病治疗指南依从性：基于2008-2016年全国医疗索赔数据库的纵向分析
基于日本2008-2016年全国医疗索赔数据，分析帕金森病患者抗帕金森药物处方模式及治疗指南依从性的纵向观察性研究数据集。
基本信息
资源简介
日本帕金森病治疗指南依从性：基于2008-2016年全国医疗索赔数据库的纵向分析
【一句话概览】
本数据集是 figshare 公开的结构化表格数据集，收录 3 个文件、合计 1.31 MB，主题涵盖 anti-PD drug prescriptions、non-ergot DA combination therapy、2016 Background Adherence、treatment guideline recommendations、non-ergot DA monotherapy，可用于统计建模、特征工程与队列分析，CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《Adherence to treatment guideline recommendations for Parkinson’s disease in Japan: A longitudinal analysis of a nationwide medical claims database between 2008 and 2016》。配套论文《Adherence to treatment guideline recommendations for Parkinson’s disease in Japan: A longitudinal analysis of a nationwide medical claims database between 2008 and 2016》发表于 PLOS ONE（2020），DOI：10.1371/journal.pone.0230213。源站首次发布：2020-04-24。
【数据内容】
源站原始描述：Background Adherence to the 2011 Japanese guidelines for treatment of Parkinson’s disease (PD) in real-life practice is unknown. Methods In this retrospective longitudinal observational study, we examined patterns and trends in anti-PD drug prescriptions in 20,936 patients (≥30 years of age with newly diagnosed PD [International Classification of Diseases–Tenth code G20 or PD Hoehn and Yahr scale 1–5] and one or more prescriptions) using nationwide registry data between 2008 and 2016. Data are p…
【数据结构与技术规格】
文件数 3 个，合计 1.31 MB。pone.0230213.s001.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，57.88 KB。pone.0230213.s002.eps：image/x-eps，737.49 KB。pone.0230213.s003.eps：image/x-eps，518.62 KB。数据集 DOI：10.1371/journal.pone.0230213。
【主题与分类】
源站学科分类：Medicine、Cell Biology、Neuroscience、Pharmacology、Biotechnology、Chemical Sciences not elsewhere classified。主题标签：anti-PD drug prescriptions、non-ergot DA combination therapy、2016 Background Adherence、treatment guideline recommendations、non-ergot DA monotherapy、non-ergot dopamine agonists、monoamine oxidase-B inhibitors、L-dopa monotherapy。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面：https://plos.figshare.com/articles/dataset/Adherence_to_treatment_guideline_recommendations_for_Parkinson_s_disease_in_Japan_A_longitudinal_analysis_of_a_nationwide_medical_claims_database_between_2008_and_2016/12194046
使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。
规范引用：Suzuki, Masahiko; Arai, Masaki; Hayashi, Ayako; Ogino, Mieko (2020). Adherence to treatment guideline recommendations for Parkinson’s disease in Japan: A longitudinal analysis of a nationwide medical claims database between 2008 and 2016. PLOS ONE. Dataset
【使用注意】
· 源站最后修改于 2023-06-03，引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务（收技术服务费，非数据销售）
暂未开放当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取（Figshare）
- 源站标题：Adherence to treatment guideline recommendations for Parkinson’s disease in Japan: A longitudinal analysis of a nationwide medical claims database between 2008 and 2016
- DOI：10.1371/journal.pone.0230213
- 发布日期：2020-04-24
- 文件数：3 个
- 文件总体积：1.31 MB
- 源站页面：https://plos.figshare.com/articles/dataset/Adherence_to_treatment_guideline_recommendations_for_Parkinson_s_disease_in_Japan_A_longitudinal_analysis_of_a_nationwide_medical_claims_database_between_2008_and_2016/12194046
命令行下载
curl -L -o "pone.0230213.s001.docx" "https://ndownloader.figshare.com/files/22417587"
curl -L -o "pone.0230213.s002.eps" "https://ndownloader.figshare.com/files/22417590"
curl -L -o "pone.0230213.s003.eps" "https://ndownloader.figshare.com/files/22417596"
文件清单
pone.0230213.s001.docx（57.88 KB）pone.0230213.s002.eps（737.49 KB）pone.0230213.s003.eps（518.62 KB）
文件总体积 1.31 MB（源站 API 实测）。
数据说明
Background
Adherence to the 2011 Japanese guidelines for treatment of Parkinson’s disease (PD) in real-life practice is unknown.
Methods
In this retrospective longitudinal observational study, we examined patterns and trends in anti-PD drug prescriptions in 20,936 patients (≥30 years of age with newly diagnosed PD [International Classification of Diseases–Tenth code G20 or PD Hoehn and Yahr scale 1–5] and one or more prescriptions) using nationwide registry data between 2008 and 2016. Data are presented as descriptive statistics.
Results
Half (49.6%) of the patients received levodopa (L-dopa) monotherapy, followed by non-ergot dopamine agonists (DA) prescribed as monotherapy (8.3%) or with L-dopa (8.1%). Consistent with the guidelines, 75% of patients were prescribed within 13 days of initial diagnosis; L-dopa monotherapy was the most prescribed drug in patients ≥70 years of age, whereas non-ergot DA monotherapy was more likely to be prescribed than L-dopa in patients between 30 and 50 years of age. Inconsistent with the guidelines, L-dopa monotherapy was the most prescribed drug in patients between 51 and 69 years of age. Over the course of 4 years of treatment, the prescription rate of L-dopa monotherapy and non-ergot DA monotherapy decreased by 63.7% and 44.1%, respectively, whereas that of L-dopa and non-ergot DA combination therapy increased by 103.7%. Combination therapy with L-dopa, non-ergot DA, and monoamine oxidase-B inhibitors was gradually increased at a later stage.
Conclusion
These results highlight that the state of PD treatment in Japan adheres to most of the recommendations in the 2011 national guidelines, but also precedes the 2018 guidelines.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.1371/journal.pone.0230213（source: https://plos.figshare.com/articles/dataset/Adherence_to_treatment_guideline_recommendations_for_Parkinson_s_disease_in_Japan_A_longitudinal_analysis_of_a_nationwide_medical_claims_database_between_2008_and_2016/12194046）。
数据缺失？
依托陕西、四川两大基地，我们与超过十家三甲医院建立直接合作关系，覆盖合规授权、采集治理、专业标注、数据交付的全流程，为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务？立即联系我们获取专业方案。
